Sequoia Financial Advisors LLC Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

Sequoia Financial Advisors LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 12.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 723 shares of the biotechnology company’s stock after purchasing an additional 81 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $259,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after purchasing an additional 22,978 shares during the period. LSV Asset Management grew its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the period. Dimensional Fund Advisors LP increased its holdings in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after acquiring an additional 22,683 shares in the last quarter. Pacer Advisors Inc. raised its position in United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Finally, Swedbank AB purchased a new position in United Therapeutics during the first quarter valued at $97,316,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $352.80 on Wednesday. The company’s 50-day moving average is $354.14 and its two-hundred day moving average is $314.95. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $377.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The firm has a market capitalization of $15.65 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 1.27 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the previous year, the company posted $5.24 earnings per share. The company’s revenue was up 19.8% on a year-over-year basis. Analysts forecast that United Therapeutics Co. will post 24.72 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the sale, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,012 shares of company stock worth $36,767,286. 12.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Bank of America dropped their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $361.33.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.